Expression and significance of p53 and mdm2 in atypical intestinal metaplasia and gastric carcinoma

Wang,Lin; Zhang,Xiao-Ying; Xu,Ling; Liu,Wen-Jun; Zhang,Juan; Zhang,Jian-Ping

doi:10.3892/ol.2011.292

Expression and significance of p53 and mdm2 in atypical intestinal metaplasia and gastric carcinoma

Authors:
- Lin Wang
- Xiao-Ying Zhang
- Ling Xu
- Wen-Jun Liu
- Juan Zhang
- Jian-Ping Zhang
View Affiliations

Affiliations: Department of Pathology, Shandong University School of Medicine, Jinan, Shandong 250012, P.R. China, Department of Pathology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: April 14, 2011 https://doi.org/10.3892/ol.2011.292
Pages: 707-712

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Subtypes of intestinal metaplasia may have different manifestations in the carcinogenesis of gastric mucosa. The present study aimed to investigate expression of murine double minute gene 2 (mdm2) in atypical intestinal metaplasia (AIM) and its relationship to gastric carcinoma. Intestinal metaplasia (IM) specimens were obtained from 58 cases. Using a novel classification of IM, the specimens were classified according to morphological changes exhibited in the gastric mucosa; specifically, atypical intestinal metaplasia (AIM) and simple intestinal metaplasia (SIM). The gatric carcinoma specimens were then compared with types I, II and III IM based on different substances present in the mucous. Envision immunohistochemical technique was applied to the detection of the expression of p53 and mdm2 in 58 IM and 30 gastric carcinoma cases. Expression of both p53 and mdm2 proteins was found to be higher in gastric carcinomas (p53, 56.67%, 17/30 and mdm2, 53.33%, 16/30) and AIM (p53, 51.85%, 14/27 and mdm2, 51.85%, 14/27) as compared to SIM (p53, 25.81%, 8/31 and mdm2, 19.35%, 6/31) (P<0.05). A similar pattern of expression of mdm2 protein was found in type I (36.84%, 7/19), type II (38.46%, 10/26) and type III (23.08%, 3/13) IM and gastric carcinoma (53.33%, 16/30). p53 expression was higher in gastric carcinoma (56.67%) compared to type I IM (26.32%) (P<0.05). However, no differences were evident among type II (42.31%, 11/26), type III (46.15%, 6/13) IM and gastric carcinoma. AIM may reveal the precancerous nature of gastric carcinoma more clearly than SIM or the conventional IM subtypes. Additionally, AIM may be involved as a preneoplastic lesion and therefore be an effective indicator in the clinical follow-up of gastric carcinoma patients.

View Figures

View References

1	Burkitt MD, Varro A and Pritchard DM: Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J Gastroenterol. 15:1–16. 2009. View Article : Google Scholar : PubMed/NCBI
2	Chen XM, Chen GY, Wang ZR, Zhu FS, Wang XL and Zhang X: Detection of micrometastasis of gastric carcinoma in peripheral blood circulation. World J Gastroenterol. 10:804–808. 2004.PubMed/NCBI
3	Nakajima N, Ito Y, Yokoyama K, Uno A, Kinukawa N, Nemoto N and Moriyama M: The expression of murine double minute 2 (MDM2) on helicobacter pylori-infected intestinal metaplasia and gastric cancer. J Clin Biochem Nutr. 44:196–202. 2009. View Article : Google Scholar : PubMed/NCBI
4	Leung WK and Sung JJ: Review article: intestinal metaplasia and gastric carcinogenesis. Aliment Pharmacol Ther. 16:1209–1216. 2002. View Article : Google Scholar : PubMed/NCBI
5	Jass JR: Role of intestinal metaplasia in the histogenesis of gastric carcinoma. J Clin Pathol. 33:801–881. 1980. View Article : Google Scholar : PubMed/NCBI
6	Jass JR and Filipe MI: A variant intestinal metaplasia associated with gastric carcinoma: a histochemical study. Histopathology. 3:191–199. 1979. View Article : Google Scholar : PubMed/NCBI
7	Dixon MF: Campylobacter and chronic gastritis. Campylobacter and Gastroduodenal Disease. Rathbone BJ and Heatley RV: Blackwell Scientific Publications; Oxford: pp. 1061–1116. 1989
8	Sipponen P and Hyvainen H: Role of helicobacter pylori in the pathogenesis of gastric peptic ulcer and gastric cancer. Scand J Gastroenterol Suppl. 196:3–6. 1993.
9	Dixon MF: Pathophysiology of helicobacter pylori infection. Scand J Gastroenterol Suppl. 201:7–10. 1994.
10	Rothery GA and Day DW: Intestinal metaplasia in endoscopic biopsy specimens of gastric mucosa. J Clin Pathol. 38:613–621. 1985. View Article : Google Scholar : PubMed/NCBI
11	Ectors N and Dixon MF: The prognostic value of sulphomucin positive intestinal metaplasia in the development of gastric cancer. Histopathology. 10:1271–1277. 1986. View Article : Google Scholar : PubMed/NCBI
12	Petersson F, Borch K and Franzén LE: Prevalence of subtypes of intestinal metaplasia in the general population and in patients with autoimmune chronic atrophic gastritis. Scand J Gastroenterol. 37:262–266. 2002. View Article : Google Scholar : PubMed/NCBI
13	Zheng Y, Wang L, Zhang JP, Yang JY, Zhao ZM and Zhang XY: Expression of p53, c-erbB-2 and Ki67 in intestinal metaplasia and gastric carcinoma. World J Gastroenterol. 16:339–344. 2010. View Article : Google Scholar : PubMed/NCBI
14	Barak Y, Juven T, Haffner R and Oren M: mdm2 expression is induced by wild type p53 activity. EMBO J. 12:461–468. 1993.PubMed/NCBI
15	Momand J and Zambetti GP: Mdm-2: ‘big brother’ of p53. J Cell Biochem. 64:343–352. 1997.
16	Lev Bar-Or R, Maya R, Segel LA, Alon U, Levine AJ and Oren M: Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc Natl Acad Sci USA. 97:11250–11255. 2000.PubMed/NCBI
17	Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW and Vogelstein B: p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 53:2231–2234. 1993.PubMed/NCBI
18	Leite KR, Franco MF, Srougi M, Nesrallah LJ, Nesrallah A, Bevilacqua RG, Darini E, Carvalho CM, Meirelles MI, Santana I and Camara-Lopes LH: Abnormal expression of MDM2 in prostate carcinoma. Mod Pathol. 14:428–436. 2001. View Article : Google Scholar : PubMed/NCBI
19	Reis CA, David L, Nielsen PA, Clausen H, Mirgorodskaya K, Roepstorff P and Sobrinho-Simões M: Immunohistochemical study of MUC5AC expression in human gastric carcinomas using a novel monoclonal antibody. Int J Cancer. 74:112–121. 1997. View Article : Google Scholar : PubMed/NCBI
20	Jass JR and Filipe MI: The mucin profile of normal gastric epithelium, intestinal metaplasia and gastric carcinoma. Histochem J. 13:831–939. 1981.
21	Hwang JH: To perform a biopsy or not to perform a biopsy? Does confocal endomicroscopy provide the answer for surveillance in Barrett’s esophagus? Gastrointest Endosc. 70:655–657. 2009.
22	Liu H, Li YQ, Yu T, Zhao YA, Zhang JP, Zhang JN, Guo YT, Xie XJ, Zhang TG and Desmond PV: Confocal endomicroscopy for in vivo detection of microvascular architecture in normal and malignant lesions of upper gastrointestinal tract. J Gastroenterol Hepatol. 23:56–61. 2008.PubMed/NCBI
23	Vogelstein B and Kinzler KW: p53 function and dysfunction. Cell. 70:523–526. 1992. View Article : Google Scholar
24	Harris AL: Mutant p53 - the commonest genetic abnormality in human cancer? J Pathol. 162:5–6. 1990. View Article : Google Scholar : PubMed/NCBI
25	Correa P and Shiao YH: Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res. 54:1941–1943. 1994.PubMed/NCBI
26	Tahara E, Kuniyasu H, Yasui W and Yokozaki H: Gene alterations in intestinal metaplasia and gastric cancer. Eur J Gastroenterol Hepatol. 6:97–101. 1994.
27	Shiao YH, Ruqqe M, Correa P, Lehmann HP and Scheer WD: p53 alteration in gastric precancerous lesions. Am J Pathol. 144:511–517. 1994.PubMed/NCBI
28	Uchino S, Noguchi M, Ochiai A, Saito T, Kobayashi M and Hirohashi S: p53 mutation in gastric cancer: a genetic model for carcinogenesis is common to gastric and colorectal cancer. Int J Cancer. 54:759–764. 1993. View Article : Google Scholar : PubMed/NCBI
29	Maesawa C, Tamura G, Suzuki Y, Ogasawara S, Sakata K, Kashiwaba M and Satodate R: The sequential accumulation of genetic alterations characteristic of the colorectal adenoma-carcinoma sequence does not occur between gastric adenoma and adenocarcinoma. J Pathol. 176:249–258. 1995. View Article : Google Scholar
30	Tamura G, Sato K, Akiyama S, Tsuchiya T, Endoh Y, Usuba O, Kimura W, Nishizuka S and Motoyama T: Molecular characterization of undifferentiated-type gastric carcinoma. Lab Invest. 81:593–598. 2001. View Article : Google Scholar : PubMed/NCBI
31	Ranzani GN, Luinetti O, Padovan LS, Calistri D, Renault B, Burrel M, Amadori D, Fiocca R and Solcia E: p53 gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type. Cancer Epidemiol Biomarkers Prev. 4:223–231. 1995.PubMed/NCBI
32	Ochiai A, Yamauchi Y and Hirohashi S: p53 mutations in the non-neoplastic mucosa of the human stomach showing intestinal metaplasia. Int J Cancer. 69:28–33. 1996. View Article : Google Scholar : PubMed/NCBI
33	Oliner JD, Kinzler KW, Meltzer PS, George DL and Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 358:80–83. 1992. View Article : Google Scholar : PubMed/NCBI
34	Bueso-Ramos CE, Manshouri T, Haidar MA, Huh YO, Keating MJ and Albitar M: Multiple patterns of MDM-2 deregulation in human leukemias: implications in leukemogenesis and prognosis. Leuk Lymphoma. 17:13–18. 1995. View Article : Google Scholar : PubMed/NCBI
35	Iwakuma T and Lozano G: MDM2, an introduction. Mol Cancer Res. 1:993–1000. 2003.
36	Günther T, Schneider-Stock R, Häckel C, Kasper HU, Pross M, Hackelsberger A, Lippert H and Roessner A: Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations. Mod Pathol. 13:621–626. 2000.PubMed/NCBI
37	Tanière P, Martel-Planche G, Maurici D, Lombard-Bohas C, Scoazec JY, Montesano R, Berger F and Hainaut P: Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia. Am J Pathol. 158:33–40. 2001.PubMed/NCBI